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Abstract
In clinic studies, altered hypothalamic-pituitary-adrenal (HPA)
axis function has been associated with fibromyalgia, a syndrome
characterised by chronic widespread body pain. These results
may be explained by the associated high rates of psychological
distress and somatisation. We address the hypothesis that the
latter, rather than the pain, might explain the HPA results. A
population study ascertained pain and psychological status in
subjects aged 25 to 65 years. Random samples were selected
from the following three groups: satisfying criteria for chronic
widespread pain; free of chronic widespread pain but with
strong evidence of somatisation ('at risk'); and a reference
group. HPA axis function was assessed from measuring early
morning and evening salivary cortisol levels, and serum cortisol
after physical (pain pressure threshold exam) and chemical
(overnight 0.25 mg dexamethasone suppression test) stressors.
The relationship between HPA function with pain and the
various psychosocial scales assessed was modelled using
appropriate regression analyses, adjusted for age and gender. In
all 131 persons with chronic widespread pain (participation rate
74%), 267 'at risk' (58%) and 56 controls (70%) were studied.
Those in the chronic widespread pain and 'at risk' groups were,
respectively, 3.1 (95% CI (1.3, 7.3)) and 1.8 (0.8, 4.0) times
more likely to have a saliva cortisol score in the lowest third.
None of the psychosocial factors measured were, however,
associated with saliva cortisol scores. Further, those in the
chronic widespread pain (1.9 (0.8, 4.7)) and 'at risk' (1.6 (0.7,
3.6)) groups were also more likely to have the highest serum
cortisol scores. High post-stress serum cortisol was related to
high levels of psychological distress (p = 0.05, 95% CI (0.02,
0.08)). After adjusting for levels of psychological distress, the
association between chronic widespread pain and post-stress
cortisol scores remained, albeit slightly attenuated. This is the
first population study to demonstrate that those with
established, and those psychologically at risk of, chronic
widespread pain demonstrate abnormalities of HPA axis
function, which are more marked in the former group. Although
some aspects of the altered function are related to the
psychosocial factors measured, we conclude that the
occurrence of HPA abnormality in persons with chronic
widespread pain is not fully explained by the accompanying
psychological stress.
Introduction
Fibromyalgia is a common syndrome of which chronic wide-
spread body pain is the cardinal feature [1]. We have previ-
ously shown in a community-based prospective cohort study,
the Altrincham Pain Study, that psychosocial factors, including
reporting other non-pain somatic symptoms, aspects of illness
behaviour and high levels of psychological distress and
fatigue, were the strongest predictors of the onset of chronic
widespread pain [2]. The biological processes through which
these psychosocial risk factors may lead to pain, however, are
unknown.R992
CI = confidence interval; CWP = chronic widespread pain; GHQ = General Health Questionnaire; HAD = Hospital Anxiety and Depression; HPA = 
hypothalamic-pituitary-adrenal; IQR = inter-quartile range; OR = odds ratio; PCA = principal component analysis.
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R993One hypothesis, although the link is debated [3,4], relates to
altered function of the hypothalamic-pituitary-adrenal (HPA)
stress axis [5]. Specifically, clinic patients with fibromyalgia
have been reported to have hypoactive HPA axis function, with
several studies showing reduced basal plasma cortisol,
decreased 24-h urinary free cortisol excretion [6-9] and a
blunted response to dynamic testing [9-11], Further, pain sen-
sitivity is inversely related to the level of activation of the HPA
system's response to stress. The hypoactive HPA axis
response of fibromyalgia patients is more marked when com-
pared to that of other chronic pain patients with less wide-
spread symptoms, including those with rheumatoid arthritis [7]
and non-inflammatory low back pain [9]. These findings are
equivocal, however, with some investigators reporting that
patients with fibromyalgia display hyperactive HPA responses
[7,8,12,13].
The nature of the relationship between chronic widespread
pain and HPA axis function is therefore unclear and remains to
be clarified. The studies discussed above were conducted on
small numbers of patients, which may have had an impact on
the accuracy of the findings. More importantly, subjects with
chronic widespread pain, when compared to pain free con-
trols, have increased rates of other symptoms, including high
levels of psychological distress [14], notably depressive disor-
ders [15], which are associated with altered HPA axis func-
tion. Indeed, mood disorders are even more apparent in those
who consult with pain [16]. We have conducted a study to
investigate the independent effects of pain and psychological
distress in relation to the HPA response.
Methods
Design
We conducted a cross-sectional population-based study in
which groups of subjects were identified based on their pain
and psychological status and whose HPA axis function was
assessed. Subjects completed a questionnaire that enquired
about aspects of psychological status together with a history
of current pain. Those who agreed to further contact by the
study team were asked if they would be willing to further par-
ticipate in a detailed assessment that included measures of
HPA axis function. Of those persons agreeing, several sub-
jects had to be excluded (Additional file 1), as accurate HPA
assessment in them would not have been possible. Of those
remaining, random samples of subjects stratified by pain and
psychological distress status were subsequently invited to
attend.
Study sampling frame
Subjects were recruited from the population registers of indi-
viduals eligible to receive care from three primary care physi-
cians in the United Kingdom. In total 2,312 subjects aged
between 25 and 65 years completed the questionnaire, were
eligible to participate further, and formed the sampling frame
for the study.
Ascertainment of pain and psychological status
All subjects completed a questionnaire that included a blank
body manikin on which subjects were asked to indicate the
site of any pain lasting at least 24 h or more in the past month.
The questionnaire also included the following items to ascer-
tain psychological status, including several scales we have
previously demonstrated to be associated with the develop-
ment and persistence of chronic widespread pain [2,17].
The General Health Questionnaire
The General Health Questionnaire (GHQ) [18] is a 12-item
questionnaire that was originally developed as a screening
instrument for mental disorder in the community. It has been
widely used in population-based studies as a measure of psy-
chological distress. Each item response scores 0 or 1. Total
scores range from 0 to 12, with higher scores indicating
higher levels of psychological distress.
The Illness Attitude Scales
The nine scales of the Illness Attitude Scales [19] individually
measure worries about health, concern about pain, hypochon-
driacal beliefs, health habits, bodily preoccupation, fear of
dying, disease phobia, treatment experience and effect of
symptoms. Based on the scores generated, two subscales
have been identified, Health Anxiety and Illness Behaviour
[21].
The Hospital Anxiety and Depression scales
The Hospital Anxiety and Depression (HAD) [21] was origi-
nally developed for use in patients with physical illnesses but
is widely used in population-based studies. The 14 items, each
being scored on a 0 to 3 scale, measure degrees of anxiety
(seven items) and depression (seven items). The two subscale
scores thus range from 0 to 21, with higher scores indicating
an increased likelihood of an anxiety or depressive disorder
being present.
The List of Threatening Experiences
The List of Threatening Experiences [22] is a 12-event inven-
tory initially modified by Bebbington and colleagues [22] from
a 67 life-events inventory introduced by Tennant and Andrews
[23]. The categories ask about recent adverse experiences of
personal relationships, employment, illness, and financial and
legal issues in the last six months.
The Sleep Problem Scale
The Sleep Problem Scale [24] contains four items that exam-
ine recent problems with sleep. Responses are scored in a
range of 0 to 5, giving a total score of between 0 and 20.
Higher scores indicate increased sleep disturbance.
Classification of study groups
To examine the study hypotheses three groups of subjects,
classified according to their pain reports and psychological
status, were selected to participate in an assessment of their
Available online http://arthritis-research.com/content/7/5/R992
R994HPA axis function. Informed consent to participate in the study
was sought from all subjects.
Chronic widespread pain group
This group of subjects comprised those with chronic wide-
spread pain, classified according to the American College of
Rheumatology criteria [1]. This group of subjects included all
those who satisfied those criteria, irrespective of their tender
point count.
'At risk' group
This group of subjects comprised those without chronic wide-
spread pain but who, based on their psychological status
(reporting three or more symptoms on the Somatic Symptom
Checklist and scoring 5 or more on the Illness Behaviour
Scale) and as demonstrated in our previous work [2], were at
risk of its future development. This group of subjects have
many features in common with the Chronic widespread pain
group, though were free of chronic widespread pain.
Reference group
A group of individuals who neither had current chronic wide-
spread pain nor showed evidence of being psychologically
distressed were classified as a reference group.
Assessment of HPA axis function
Methods were selected appropriate for undertaking in large
samples of community dwelling subjects, though there are no
standardised methods of assessing HPA function in such
studies. We therefore decided to take a broad approach and
used four measures of axis function: two that assessed HPA
tone using salivary cortisol levels and two that assessed HPA
response to different stimuli based on serum levels. Salivary
cortisol affords a convenient method of assessment that pro-
vides a valid and reliable correlate of serum/plasma free diur-
nal cortisol levels [25,26]. This method is easy to administer,
especially in studies recruiting large numbers of subjects, and
minimises disruption to participants' lives.
Subjects collected the salivary cortisol levels in the evening (at
10 pm) and the following morning (between 8 am and 9 am).
Serum cortisol levels were measured after an overnight 0.25
mg dexamethasone suppression test and a physical (pain
pressure threshold examination) stressor (see Additional file 2
for sample collection schedule).
Hormone assays
Plasma cortisol was determined using the Chiron Diagnostic
ACS:180 analyser (Bayer HealthCare LLC Diagnostic Divi-
sion, New York, NY, USA). The assay is a competitive chemi-
luminescent immunoassay. Cortisol in the sample competes
with cortisol labelled with acridinium ester for a limited amount
of polyclonal rabbit anti-cortisol antibody coupled to paramag-
netic particles. The cortisol concentration in the sample is
inversely proportional to the relative light units detected in the
ACS:180 system.
A modified version of the radioimmunoassay method used for
serum cortisol was employed for assaying salivary cortisol lev-
els. This method depends on competition between cortisol
present in sample or standard and 125I-labelled cortisol for a
limited number of binding sites on rabbit ant-cortisol antibody.
Separation of the antibody-bound fraction is effected by incu-
bation with donkey anti-rabbit antibody coated to cellulose
particles followed by centrifugation and decantation of the
supernatant. The pellet is then counted and the amount of
tracer bound is inversely proportional to the concentration of
cortisol present. Before assay, the salivary sample was centri-
fuged for 5 minutes at 2500 revolutions per minute. The super-
natant was then removed for assay.
Ethical approval was sought and granted from the appropriate
Local Research Ethics Committees. The Arthritis Research
Campaign, Chesterfield, England, funded the study.
Figure 1
Flow of study subjects. CWP, chronic widespread pain.
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We compared the raw cortisol data for each of the four
assessment methods between the three groups of partici-
pants. The individual methods used to assess HPA function
were inevitably prone to random error owing to difficulties in
standardising collection procedures in the home environment.
We therefore examined whether an approach that combined
the four sources of cortisol data would be more informative. To
do this we used a principal component analysis (PCA), a sta-
tistical technique that reduces the complexity of a number of
inter-correlated variables by reduction of the observed data to
a smaller number of uncorrelated variables called the principal
components. The individual values of the observed variables
contribute ('load on') to the resulting component scores,
which are calculated for each subject. PCA analysis produces
eigenvalues, a measure of the variance that is explained by the
individual components. Importantly, PCA does not require
prior assumptions about individual variable interactions. Con-
ventionally, eigenvalues over 1 are said to explain more of the
variance than the raw data alone. For analysis, the resulting
principal component scores were categorized into tertiles
based upon the distribution of scores with the highest or low-
est tertile classified as the referent category. The relationship
with those persons 'at risk' of, or having chronic widespread
pain compared to the reference group and component scores
was expressed as Odds Ratios (ORs) with 95% confidence
intervals (CI). The relationship between component scores
and psychosocial scales was modelled using linear regres-
sion. Due to high correlation coefficients (r > 0.4), we removed
the HAD anxiety (correlated with the GHQ and Health Anxiety
scale) and HAD depression (correlated with the GHQ and
Sleep scale) subscales from this analysis. All analyses were
adjusted for the potential confounding effects of age and
gender.
Results
Response and participation rates
Of the 2,312 eligible subjects, 497 (13%) had chronic wide-
spread pain, 768 (21%) were free of chronic widespread pain
but at risk of its future development, and 1047 (28%) were in
the reference group (Fig. 1). Random samples of 178, 463
and 80 subjects from each of these three groups, respectively,
were telephoned and invited to the assessment of HPA axis
function of which 131 (74%), 267 (58%) and 56 (70%),
Figure 2
Distribution (median, inter-quartile range) of cortisol levels by study group. CWP, chronic widespread pain.
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tion of the questionnaire variables between those subjects
within each of these three sample groups who did and did not
agree to participate was undertaken and showed no evidence
of non-participation bias (data not shown). A total of 429 sub-
jects (125 with chronic widespread pain, 254 at risk and 50
controls) provided all four measures of HPA axis function and
were included in the current analysis. The cortisol data were
examined for outliers, with values more than 4 standard devia-
tions from the mean being eliminated. This procedure resulted
in four (0.9%) observations being removed (one person with
chronic widespread pain and three 'at risk'), leaving a total of
425 subjects for analysis. Of those who participated, there
were no significant differences between the three groups in
age or gender (Table 1); however, persons 'at risk' and those
with chronic widespread pain, as expected, had significantly
higher scores on all of the psychosocial scales when com-
pared to the reference group.
Results from the principal components analysis
An examination of the raw data revealed a tendency towards
lower saliva cortisol levels and higher post-stress levels in both
those at risk and those with established chronic widespread
pain (Fig. 2, Table 2). The PCA yielded four composite cortisol
scores (Table 3), three of which had eigenvalues above or
approaching 1. These three components were interpreted as:
a 'saliva cortisol' score that was composed of the evening and
morning cortisol values; a 'post-stress cortisol' score that was
composed of the post-dexamethasone and post-physical
exam cortisol scores; and a 'post-stress difference' cortisol
score that was composed of the difference between post-dex-
amethasone and post-physical exam scores. These three com-
ponents were used in all further analyses.
Principal components of HPA function and pain
Compared to the reference group, those persons at risk of
future chronic widespread pain were 1.8 times more likely to
Figure 3
Results of logistic regression models of the association between study groups and cortisol levels. All analyses were adjusted for age and gender. 
CWP, chronic widespread pain.
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chronic widespread pain were three times more likely (Fig. 3a).
Both subjects 'at risk' and those with chronic widespread pain
had higher, though non-significant, post-stress cortisol scores,
being 1.6 and 1.9-times more likely, respectively, to have the
highest post-stress serum cortisol scores when compared to
the reference group (Fig. 3b). Neither being at risk of nor hav-
ing chronic widespread pain was associated with post-stress
difference scores (Fig. 3c).
The relationships between HPA axis function and being in the
'at risk' or chronic widespread pain groups compared to the
reference group were strong, although, as discussed above,
may have been explained by the presence of psychosocial fac-
tors. We therefore examined the relationship between psycho-
social factors and HPA axis function. A linear regression
analysis revealed that none of the psychosocial factors meas-
ured were associated with saliva cortisol scores (Table 4).
Higher levels of psychological distress, however, were associ-
ated with higher post-stress serum cortisol scores (β = 0.05,
95% CI (0.02, 0.08)) and, although not statistically significant,
recent life events also showed a positive association. After
adjusting for the effects of these variables, the relationship
between being at risk of (OR = 1.3, 95% CI (0.5, 3.0)) or
having chronic widespread pain (OR = 1.8, 95% CI (0.7, 4.6))
and post-stress cortisol scores was further attenuated.
Discussion
Clinic based studies have suggested that persons with
chronic widespread pain display altered HPA axis function.
Due to small numbers of subjects and the presence of psycho-
logical factors that may confound the association, however,
the true relationship remained unclear. In this, the first commu-
nity-based study, we have demonstrated that chronic wide-
spread pain was associated with altered HPA axis function.
Specifically, the presence of chronic widespread pain was
associated with lower levels of salivary cortisol and higher lev-
els of post-stressor serum cortisol. Interestingly, one would
expect, under normal circumstances, an exaggerated HPA
response to the pain threshold examination and a blunted
response following the dexamethasone suppression test as
these two measures, although 'stress response' measures, are
testing different functions of the HPA axis. Our data indicate
that both a high post-pain threshold level of cortisol and a fail-
ure to suppress after the dexamethasone suppression test
were associated with having chronic widespread pain. High
Table 1
Distribution of age, gender and scale score by pain group
Controls (N = 50) At risk (N = 251) p-valuea CWP (N = 124) p-valueb
n % n % n %
Age group
25–43 16 32 91 36 40 30
44–54 18 36 78 31 46 37
55–65 16 32 82 33 0.85 38 33 0.78
Gender
Female 30 60 165 66 0.44 74 60 0.97
Median IQR Median IQR Median IQR
Sleep 3 0–5 6 3–11 0.00 9 5–13 0.00
GHQ 0 1–1.5 1 0–5 0.00 1 0–5 0.00
Somatic symptoms 0 0-0 1 1–2 0.00 1 0–2 0.00
Health anxiety 8 4–11 11 6–15 0.00 9 6–15 0.03
Illness behaviour 2 1–4 6 5–9 0.00 6 4–10 0.00
HAD: anxiety 4 2–7 6 4–9 0.00 7 4–10 0.00
HAD: depression 1 1–4 3 1–6 0.00 5 2–7 0.00
Life events 0 0–1 1 0–2 0.01 1 0–2 0.00
aAt risk compared to controls. bCWP compared to controls. All p-values were by Mann-Whitney U test except those for sex, which were by chi-
square test. CWP, chronic widespread pain; GHQ, General Health Questionnaire; HAD, Hospital Anxiety and Depression scale; IQR, inter-
quartile range.
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Distribution of cortisol levels by pain group
Cortisol measures (nmol/l) Controls (N = 50) At risk (N = 251) CWP (N = 124)
Median IQR Median IQR Median IQR
Saliva
Morning (nmol/l) 5 3–7 5 3–8 4 2–7
Evening (nmol/l) 1 0.5–1 0.5 0.5–1 0.5 0.5–1
Serum
Post-physical exam (nmol/l) 295 229–362 310 215–387 331 240–410
Post-suppression test (nmol/l) 249 154–313 232 133–368 253 144–388
CWP, chronic widespread pain; IQR, inter-quartile range.
Table 3
Results of principal components analysis
Component loadings
1 2 3 4
Post exam serum -0.14 0.68 0.71 0.04
Post dexamethasone serum -0.08 0.71 -0.70 0.04
Saliva morning 0.69 0.15 0.03 -0.70
Saliva evening 0.70 0.07 0.03 0.71
Eigenvalue 1.89 1.18 0.81 0.13
Variance explained (%) 47 29 20 3
Table 4
Association between psychosocial scales and cortisol levels
Scale Component
Saliva Post-stress Post-stress difference
β 95% CI β 95% CI β 95% CI
Sleep -0.003 -0.006, 0.001 0.009 -0.011, 0.028 0.005 -0.011, 0.021
GHQ -0.004 -0.010, 0.002 0.052a 0.021a, 0.083a 0.008 -0.017, 0.034
Somatic symptoms 0.023 -0.002, 0.048 -0.097 -0.231, 0.037 0.086 -0.022, 0.193
Illness behaviour 0.004 -0.002, 0.010 -0.011 -0.040, 0.019 -0.026 -0.050, -0.002
Health anxiety -0.000 -0.003, 0.003 0.012 -0.003, 0.027 0.013 0.000, 0.025
Recent life events 0.001 -0.014, 0.016 0.040 -0.039, 0.119 0.024 -0.042, 0.090
Analyses have been adjusted for age and gender. aStatistically significant results. CI, confidence interval; GHQ, General Health Questionnaire.
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with salivary cortisol levels, although the relationship with high
levels of post-stress serum cortisol was explained to some
extent by the presence of psychological distress.
In considering these results it is useful to highlight some of the
methodological issues that may have had an impact on our
findings. First, a number of those subjects who were invited to
participate refused to do so. On analysis of the questionnaire
data within the groups selected to participate we found that
there were no significant differences in the age, gender or
psychological status between those who did and did not
agree. Second, and more importantly, the measures used to
assess HPA function were not as rigorous as those used in
laboratory based studies, although they were more wide-rang-
ing. In addition, since subjects were relied upon to take the
dexamethasone tablets and collect the salivary samples in the
absence of a member of the study team, we did not have as
much control over the sample collection. These factors are
likely to have introduced 'noise' into the data collected and,
because it is likely that any deviance from the study schedule
was random across the study groups, such 'noise' would act
to make it harder to find an association. That being the case, it
is also likely that any association we have reported is an under-
estimate of the true association.
There are no comparable community-based studies with
which to compare our findings, although clinic based studies
of fibromyalgia patients have reported a range of HPA axis dis-
ruptions. Thus, Crofford and colleagues [8] reported that fibro-
myalgia clinic patients had low 24-h urinary free cortisol levels
and low levels of cortisol in response to challenge with ovine
corticotropin-releasing hormone when compared to age- and
sex-matched pain free controls. Griep and colleagues [9]
examined the HPA axis function in a group of 40 patients with
fibromyalgia, 28 with non-inflammatory low back pain and 14
pain free controls. Compared to the pain free control subjects,
those with fibromyalgia displayed mild hypocortisolemia and
significantly lower levels of 24-h urinary free cortisol. Subjects
with low back pain showed similar perturbations but to a lesser
extent than those observed in the group of fibromyalgia
patients.
Conclusion
We have previously shown that psychological status is a
strong predictor of the onset of chronic widespread pain [2],
although the biological mechanism through which such fac-
tors may lead to pain was unclear. The altered HPA function
evident in subjects in the present study is one possible mech-
anism. We propose that the impaired HPA axis tone as shown
by the low salivary cortisol measurements indicates a failure to
mount an adequate stress response to psychological insult,
and that this failure predisposes to the development of chronic
widespread pain. However, this model can only be examined
in a prospective study. To that end we are following-up those
persons in the current study who were 'at risk' of the future
development of symptoms to determine whether, among that
group of subjects who are psychologically distressed, altered
HPA function predicts symptom onset.
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